Core Viewpoint - The Hong Kong Stock Connect innovative drug sector has experienced a continuous adjustment for six days, with the Hong Kong Stock Connect Innovative Drug ETF (520880) showing a decline of 0.75% and a trading volume of 200 million [1]. Group 1: Market Performance - The innovative drug ETF (520880) is fully invested in innovative drug R&D companies and has recently attracted significant capital inflows, indicating a potential opportunity for investment in innovative drugs [3][12]. - The leading pharmaceutical companies are expected to have promising earnings forecasts for 2025, which could lead to valuation recovery opportunities [3][12]. - The ETF has seen a recent increase in fund size to 2.348 billion, with the number of shares reaching 4.382 billion, both hitting new highs since its listing [4][10]. Group 2: Long-term Outlook - The core logic of the Hong Kong Stock Connect innovative drug sector remains solid, with expectations of a total overseas licensing amount for innovative drugs reaching 135.7 billion in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][12]. - The National Medical Products Administration (NMPA) is expected to approve 76 innovative drugs in 2025, leading the world in approvals, and will continue to optimize the review and approval process for innovative drugs [3][12]. - Investment strategies from Zhongtai International and Guosen Securities recommend continued focus on the innovative drug sector for 2026 [3][12]. Group 3: ETF Characteristics - The ETF exclusively covers innovative drug R&D companies, excluding CXO, and has a significant concentration in leading companies, with the top ten innovative drug companies accounting for over 73% of the weight [5][12]. - The ETF employs a strategy to reduce the weight of less liquid component stocks, effectively managing tail risks [6][12]. - The ETF's tracking index has a notable advantage with a high concentration of leading companies, enhancing its investment value [7][12].

Core Insights - The article discusses the critical strategic transition period for major Chinese pharmaceutical companies, highlighting the shift from raw materials to innovative drugs as a significant phase from 2012 to 2020, and the upcoming "rebirth period" from 2024 to 2026, where companies will face asset clearance and build global competitiveness [1][2]. Industry Transformation Core Logic - The transformation involves a stabilization at the bottom of the market as the risks from centralized procurement are fully released by 2025, allowing companies to build a solid development safety margin [3]. - Companies are reinforcing their competitive advantages in key therapeutic areas despite facing patent cliffs, with new clinical evidence expected to reshape the ischemic stroke emergency market [3]. - The internationalization of leading companies is being re-evaluated, with overseas licensing agreements providing stable cash flow and validating their global rights value [3]. Macro Environment and Industry Background - The Chinese pharmaceutical industry is entering a reform phase characterized by significant price pressures on mature generic drugs and older innovative drugs due to changes in medical insurance payment methods and accelerated centralized procurement [4][6]. - Large pharmaceutical companies with strong cash flow are positioned to leverage acquisition and collaboration opportunities during a capital winter, enhancing their resilience against industry cycles [6]. Financial Structure Analysis - Revenue data from 2020 to 2025 shows a transition from stable growth to structural adjustment, with total revenue expected to decline significantly in 2025 [9][10]. - The oncology sector is experiencing a notable revenue drop due to centralized procurement impacts, while the raw materials sector is showing resilience with an 11.9% growth in 2025 [10]. - Despite revenue pressures, leading companies are maintaining or increasing R&D budgets, with R&D expenses expected to account for 21.9% of revenue in 2024 [12]. Business Layout and Treatment Areas - The business landscape of transitioning pharmaceutical companies is highly diversified, with ongoing efforts in traditional areas like cardiovascular and neurological treatments, as well as high-growth sectors like oncology and immunomodulation [13]. - The neurological drugs segment remains a cornerstone, with new products expected to drive growth despite challenges from patent expirations [17]. - The oncology sector is undergoing restructuring with the introduction of differentiated new products to support recovery [18]. - The anti-infection sector is showing resilience, driven by increased demand for antibiotics due to seasonal illnesses [19]. R&D Pipeline and Innovation Ecosystem - Leading companies have established a comprehensive innovation ecosystem with multiple technology platforms, including ADCs and GLP-1 products, with over 300 projects in development by the end of 2025 [20][25]. - ADC technology is highlighted as a key area of competitive advantage, with promising products in clinical trials [22]. - The GLP-1 product matrix is being developed to capture the growing market for weight loss and diabetes management, with several products in advanced clinical stages [25]. Key Clinical Milestones for 2026 - 2026 is anticipated to be a pivotal year for the realization of innovation pipeline results, with several core products expected to achieve significant clinical milestones [26][27].

Core Viewpoint - Lijun Group's research indicates significant advancements in its biopharmaceutical platform, focusing on autoimmune, reproductive, and vaccine sectors, with key products nearing approval and promising clinical results [1][4][5] Group 1: Autoimmune Sector - Lijun Biopharmaceutical's core product, Lakanqita monoclonal antibody, shows a PASI100 response rate of 49.5% in severe psoriasis, outperforming the control group at 40.2%, and is expected to receive approval by the end of this year [1][6][7] - The company has completed Phase III clinical trials for ankylosing spondylitis, with approval anticipated next year, and significant sales growth for another product, tocilizumab, is expected in 2025 [1][4] Group 2: Reproductive Sector - The recombinant human follicle-stimulating hormone injection is expected to be approved within this year, reinforcing the company's leading position in the assisted reproductive field [1][4] Group 3: Vaccine Sector - The quadrivalent influenza recombinant protein vaccine, the first of its kind with an adjuvant, has completed Phase I safety trials and is expected to enter Phase II clinical trials in March [5] Group 4: Overseas Expansion Strategy - The company adopts a "dual-track" strategy for international expansion, focusing on licensing its innovative pipeline to mature markets and exporting formulations to emerging markets [2][9] - In Southeast Asia, the company is building a localized platform through the acquisition of IMP in Vietnam, while in South America, it is prioritizing registration and channel development in Brazil [9] Group 5: Cardiovascular Pipeline - H001, an oral direct thrombin inhibitor, is the fastest progressing project in its category in China, showing comparable efficacy to enoxaparin with a lower bleeding risk, and is preparing for Phase III trials [3][10] Group 6: GnRH Pipeline - The GnRH pipeline covers all indications and various formulations, with key products like the three-month formulation of leuprolide expected to be approved this year [11][12] Group 7: Chemical Preparation Sector - The chemical preparation sector generated 47.2 billion yuan in revenue from January to September 2025, accounting for 51.8% of the company's total revenue, serving as a core revenue support [13][14] - Future growth will be driven by product upgrades, innovative product launches, and deepening market penetration in core therapeutic areas [14][15][16]

数据来源：wind 进一步展望生物科技领域的投资前景。大家已经了解，港股为生物科技公司上市提供了得天独厚的条 件，那么当前为何要投资港股的生物科技公司？这可以从宏观背景层面进行分析。当前美联储正处于降 息周期，大家也清楚，在降息环境下，包括美国在内的境外资金更倾向于流出美股市场，转而寻找具有 成长价值的投资机会，而非停留在美股市场追求低息无风险收益，而港股很可能成为其优先选择。 在美联储新一轮防御式降息周期中，港股资产展现出比以往更优的收益弹性和流动性前景。这对于以港 股生物科技为代表的成长板块的估值修复和业绩增长，具有重要的指引意义。下方列出的时间序列图 表，重点标记了恒生生物科技指数与美联储降息周期时间节点的重要关联。可以看到，2019年7月至 2020年美联储降息期间，恒生生物科技指数就展现出了较好的业绩弹性。而从2024年至2025年年底，乃 至如今迈入2026年，在降息周期的大背景下，恒生生物科技指数很可能展现出更优的收益弹性表现。这 是我们从宏观政策角度分析得出的结论。 回归国内政策层面，未来境内尤其是港股上市的生物科技公司将获得哪些政策支持？我们能看到，行业 政策正全链条支持创新药发展。其中一个 ...

Core Viewpoint - The company expects its annual net profit attributable to shareholders for 2025 to be between 191 million and 229 million yuan, representing a year-on-year growth of 7.69% to 29.23% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between 180 million and 216 million yuan, with a year-on-year increase of 8.84% to 30.61% [1] Group 1 - The main drivers of the performance growth are the deep layout of the innovative drug pipeline, realization of value from licensing collaborations, and synergistic support from the integrated service model [1] - The company focuses on innovative drugs with global independent intellectual property rights, covering areas such as peptides, small nucleic acids, cell therapy, and gene therapy [1] - Clinical progress of core pipelines like STC007 and STC008 has been promoted, contributing to the overall growth [1] Group 2 - Licensing collaborations and revenue sharing have become key drivers of profit growth, enhancing the company's profitability [1]

展望未来，海南九芝堂药业将继续坚守创新初心，不断筑牢技术壁垒，以特色生物医药产业发展为重要 抓手，既要守护好海南珍贵的南药黎药文化遗产，也要为海南自贸港高新技术产业升级、热带特色高效 农业与生物医药产业深度融合发展贡献积极力量，书写"科技赋能特色产业"的发展新篇章。 作为承载"中华老字号"深厚底蕴的企业，九芝堂始终坚守创新驱动发展战略，在医药研发、产业升级等 多个领域持续突破，取得一系列关键性进展，为公司未来增长拓展了广阔空间。 近日，九芝堂全资子公司海南九芝堂药业顺利通过海南省科学技术厅"高新技术种子企业"认证，正式跻 身海南省高新技术"精英行动"企业体系，成为海南自贸港科技创新领域重点培育的后备力量。据悉，高 新技术种子企业是海南省为加快构建现代产业体系、助推自贸港高质量发展而遴选的核心培育对象，堪 称全省高新技术产业发展的"潜力标杆"。此次海南九芝堂药业成功入选，不仅是省级主管部门对公司在 创新开发领域不懈努力与丰硕成果的高度认可，更为企业高质量发展注入了强劲动力。 海南九芝堂药业始终以"传承南药黎药文化、创新发展医药产业"为核心使命，在特色药用资源开发领域 持续深耕。针对裸花紫珠等海南特色南药黎药品种 ...

Core Viewpoint - After eight years of backdoor listing, Luoxin Pharmaceutical Group Co., Ltd. is struggling to survive and innovate, facing significant financial challenges and a declining market value [1][2]. Financial Performance - Luoxin Pharmaceutical has accumulated losses exceeding 1.1 billion yuan since its backdoor listing, with a market value that has sharply declined from a peak of 18 billion yuan to current levels [1][2]. - The company reported a cumulative net profit of -1.139 billion yuan from 2020 to the present, indicating poor financial performance [2][7]. - As of the end of Q3 2025, the company's debt-to-asset ratio was 61.65%, with current and quick ratios below industry healthy levels, highlighting significant short-term debt repayment pressure [2]. Asset Disposal - To alleviate liquidity issues, Luoxin Pharmaceutical has resorted to selling assets, including the transfer of 100% equity in Lekang Pharmaceutical for 62.5 million yuan, significantly below its net asset value [3][4]. - This marks the second asset sale in a short period, with previous sales also aimed at improving cash flow, although they provide limited relief for upcoming debt obligations [3][4]. Research and Development - Despite emphasizing a shift towards innovative drugs, Luoxin Pharmaceutical has been reducing R&D expenditures, which fell from 205 million yuan in 2022 to 63 million yuan in the first three quarters of 2025 [5][8]. - The company currently has two innovative drugs in clinical trials and 16 active pharmaceutical ingredients under development, but the reliance on generic drugs remains high, with generics accounting for approximately 98% of its product offerings [6][8]. Market Challenges - The company faces intense competition in the generic drug market, leading to cumulative losses of approximately 2.852 billion yuan from 2022 to 2024 [7]. - Although the innovative drug "Tigecycline" has shown promising sales growth, it is insufficient to fundamentally resolve the company's financial difficulties, as the commercialization of innovative drugs is a capital-intensive and long-term process [7][8].

Group 1 - The company announced a licensing agreement for the RAY1225 injection project, allowing Qilu Pharmaceutical to produce and commercialize the drug in China, while the company retains all rights outside of China [1] - The total payment for the licensing agreement is 1 billion yuan, which includes an upfront payment of 200 million yuan and milestone payments up to 800 million yuan, along with a double-digit percentage of net sales after the product launch [1] - RAY1225 is an innovative peptide drug with global intellectual property rights, showing promising results in clinical trials for weight loss, with a weight reduction of 10.1%-15.1% after 24 weeks of treatment [2] Group 2 - The company is seeing initial success in its transformation with core products like the Compound Thrombus Tong series and Brain Thrombus Tong capsules selected for national and regional procurement, indicating a strategy of "volume for price" to maintain profitability [3] - The company has a pipeline of innovative drugs, including ZSP1601 for MASH and RAY1225 for weight loss, with several Phase III clinical trials completed [3] - The company expects revenue growth from 2.53 billion yuan in 2025 to 3 billion yuan in 2027, with net profit projections of 310 million yuan in 2025 and 570 million yuan in 2026, reflecting a significant turnaround [4]

Investment Rating - The industry investment rating is "Outperform the Market," indicating that the industry index is expected to perform better than the market by more than 5% over the next six months [31]. Core Insights - The JPMorgan Healthcare Conference highlighted six top candidate drugs in the Chinese market for 2026, with four originating from local innovative companies, showcasing their R&D capabilities that can compete with multinational brands [4]. - The report anticipates continued active merger and acquisition (M&A) transactions in the biopharmaceutical sector, with a projected global M&A transaction volume reaching $5.1 trillion in 2025, led by a 44% increase in the healthcare sector [4]. - Investment strategies suggest focusing on innovative Chinese pharmaceutical companies that are enhancing their global competitiveness, particularly in therapeutic areas like metabolism, chronic diseases, and central nervous system disorders, as well as potential technology platforms such as small nucleic acid drugs and CAR-T therapies [5]. Summary by Sections Industry Overview - The JPMorgan Healthcare Conference showcased 24 Chinese innovative pharmaceutical companies, including BeiGene and Legend Biotech, presenting their latest R&D and commercialization achievements [4]. - The report emphasizes the importance of the Chinese market, identifying six candidate drugs that are expected to make significant impacts in 2026 [4]. Investment Strategy - The report recommends focusing on innovative therapeutic areas beyond traditional oncology and immunology, such as metabolic disorders and chronic diseases [5]. - It also highlights the potential of emerging technology platforms, suggesting investment in companies that are advancing in areas like peptide drugs and small nucleic acids [5]. Market Performance - The pharmaceutical sector experienced a decline of 0.68% last week, while the Shanghai and Shenzhen 300 Index fell by 0.57%, ranking the pharmaceutical industry 17th among 27 sectors [20]. - In contrast, the Hong Kong pharmaceutical sector saw an increase of 2.38%, outperforming the Hang Seng Index, which rose by 2.56%, ranking 6th among 11 sectors [30].

Group 1 - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan for 2025, representing a year-on-year increase of 214% to 371%, driven by rising market prices of biological assets and natural growth appreciation [1] - Kaiyin Technology has withdrawn its drug registration application for Peginterferon α-2 injection, resulting in a one-time asset impairment of 110 million yuan, significantly impacting its 2025 profit [2] - Qizheng Tibetan Medicine's subsidiary has received approval for its Shiwai Longdan Flower Capsule as a national second-level protected traditional Chinese medicine, providing a seven-year market exclusivity that will enhance its competitive position [3] Group 2 - GSK has reached a final agreement to acquire RAPT Therapeutics, focusing on innovative therapies for inflammation and immune diseases, with the deal expected to close in Q1 2026 [4] - Qilu Pharmaceutical has initiated a Phase I clinical trial for QLS5316, its first dual-target antibody-drug conjugate aimed at advanced solid tumors, marking a significant step in its innovation strategy [5]